• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

1-Ethyl-4-(2-Fluoro-4-nitrophenyl)piperazine: An Overview of a Promising Compound (CAS No. 694501-34-3)

1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine, also known by its CAS number 694501-34-3, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of piperazines, which are widely used in the development of various therapeutic agents due to their versatile pharmacological properties.

The chemical structure of 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine features a piperazine ring substituted with an ethyl group and a 2-fluoro-4-nitrophenyl moiety. The presence of these functional groups imparts unique characteristics to the molecule, making it a valuable candidate for further investigation in drug discovery and development.

Recent studies have highlighted the potential of 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine in various therapeutic areas. One notable application is its use as a lead compound in the development of novel antidepressants. Research has shown that this compound exhibits selective serotonin reuptake inhibition (SSRI) properties, which are crucial for treating mood disorders such as depression and anxiety. The fluoro and nitro substituents on the phenyl ring enhance the compound's affinity for serotonin transporters, thereby improving its efficacy as an SSRI.

In addition to its potential as an antidepressant, 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine has also been explored for its anti-inflammatory properties. Preclinical studies have demonstrated that this compound can effectively reduce inflammation by modulating key signaling pathways involved in the inflammatory response. This makes it a promising candidate for treating inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic profile of 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine has been extensively studied to understand its behavior in biological systems. Research indicates that the compound exhibits good oral bioavailability and favorable pharmacokinetic parameters, making it suitable for further development into a viable drug candidate. Its metabolic stability and low toxicity profile further enhance its potential for clinical applications.

Clinical trials are currently underway to evaluate the safety and efficacy of 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine in human subjects. Preliminary results from phase I trials have shown promising outcomes, with the compound demonstrating a favorable safety profile and significant therapeutic effects. These findings have paved the way for more advanced clinical trials to explore its potential in treating various medical conditions.

The synthetic route for producing 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine has been optimized to ensure high yield and purity. The synthesis involves several steps, including the formation of the piperazine ring, introduction of the ethyl group, and substitution with the 2-fluoro-4-nitrophenyl moiety. Advanced synthetic techniques and catalysts have been employed to streamline the process, making it more efficient and cost-effective.

In conclusion, 1-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine (CAS No. 694501-34-3) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further development into therapeutic agents for mood disorders, inflammatory diseases, and other medical conditions. Ongoing research and clinical trials will continue to shed light on its full potential, contributing to advancements in drug discovery and healthcare.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)